Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Humanigen, Inc. HGEN
$0.17
-$0.01 (-4.45%)
На 18:03, 12 мая 2023
+16 958.82%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
20600840.00000000
-
week52high
3.25
-
week52low
0.09
-
Revenue
2514000
-
P/E TTM
0
-
Beta
-0.86539700
-
EPS
-0.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Neutral | Buy | 13 июл 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 13 июл 2022 г. |
| Cantor Fitzgerald | Neutral | Overweight | 13 июл 2022 г. |
| Jefferies | Hold | Buy | 10 сент 2021 г. |
| JP Morgan | Underweight | Neutral | 09 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Durrant Cameron | A | 808906 | 808906 | 27 июл 2022 г. |
| Xie Yili Kevin | A | 83418 | 83418 | 27 июл 2022 г. |
| MORRIS TIMOTHY E | A | 600360 | 600360 | 27 июл 2022 г. |
| Jordan Edward P. | A | 455010 | 455010 | 27 июл 2022 г. |
| Boehm Rainer J. | A | 73307 | 73307 | 27 июл 2022 г. |
| Chappell Dale | A | 518205 | 518205 | 27 июл 2022 г. |
| BARLIANT RONALD | A | 55612 | 55612 | 27 июл 2022 г. |
| Buxton Cheryl | A | 78362 | 78362 | 27 июл 2022 г. |
| Kilcoyne Adrian | A | 537164 | 537164 | 27 июл 2022 г. |
| Hohneker John | A | 63195 | 63195 | 27 июл 2022 г. |
Новостная лента
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
24/7 Wall Street
24 окт 2022 г. в 21:21
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
Newsfile Corp
07 сент 2022 г. в 06:55
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C.
Why Is Humanigen (HGEN) Stock Down 16% Today?
InvestorPlace
29 авг 2022 г. в 09:03
Source: shutterstock.com/PhotobyTawat Humanigen (NASDAQ: HGEN ) stock is heading lower on Monday as investors react to a delisting notice from the Nasdaq Exchange. According to a filing with the U.S. Securities and Exchange Commission (SEC), HGEN stock has been unable to maintain the minimum bid price of $1 per share to remain on the market.
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
12 авг 2022 г. в 18:48
Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
Zacks Investment Research
14 июл 2022 г. в 13:10
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.